• 
  Clinical Trial Shows that Treatment with Kerecis Intact Fish-Skin Grafts Shortens Hospital Stays for Severely Burned Patients16 April 2026, 2:03 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #kerecis--Study shows Kerecis fish-skin grafts reduce hospital stays for burn patients by 9.3 days compared to synthetic grafts, with lower complication rates.

• 
  Catalyst OrthoScience Demonstrates Leadership in Procedural Efficiency with Addition of Fracture to Its Single-Tray Portfolio16 April 2026, 2:00 pm

  NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the expansion of its single-tray portfolio, with the introduction of a single tray option for the Catalyst Fracture system, at the upcoming Shoulder360™ Annual Meeting. This milestone represents a significant advancement in shoulder surgery workflow efficiency and gives surgeons partne

• 
  Starfighters Space, Inc. files Fiscal 2025 Annual Report16 April 2026, 12:50 am

  CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world’s largest fleet of commercial supersonic aircraft, is pleased to report, in accordance with NYSE American requirements, the filing of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). This Form 10-K filing, which in

• 
  SurGenTec Secures FDA 510(k) Clearance for TiLink™ SI joint fusion- Now Navigation Compatible15 April 2026, 4:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)---- $ISRG #FDAcleared--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its TiLink™ Navigation Instruments for use with the TiLink™ SI Joint Fusion System in sacroiliac joint procedures. The system is engineered for compatibility with Medtronic’s StealthStation™ navigation platform, enabling enhanced precision during minimally invasive SI joint fusion surgeries.

• 
  Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution15 April 2026, 1:51 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #amlodipine--Sdamlo, by Pangea Pharmaceuticals, is an FDA-approved amlodipine, unit-dose, alcohol-free solution for pediatric, geriatric, and tube-fed patients.

• 
  Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results14 April 2026, 9:00 pm

  OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i

• 
  Orlando Community Unites at 2026 Susan G. Komen® MORE THAN PINK Walk14 April 2026, 3:37 pm

  ORLANDO--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, will bring together breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the Central Florida MORE THAN PINK Walk on Saturday, May 9, 2026. The Orlando community will come together to make sure no one faces breast cancer alone and help advance Komen’s mission to save lives through research, public policy, education and care. This year, Komen aims to raise $210,000 at

• 
  LifeStream Behavioral Center and Greenspace Health Partner to Advance Data-Informed Behavioral Healthcare Across Central Florida14 April 2026, 1:03 pm

  TORONTO & LEESBURG, Fla.--(BUSINESS WIRE)-- #CARF--Greenspace Health and LifeStream Behavioral Center, a leading nonprofit provider of behavioral health and social services in Central Florida, have partnered to implement Measurement-Based Care (MBC) across LifeStream’s full continuum of programs. The collaboration will leverage data-driven insights and patient-reported outcome measures (PROMs) within the care process to improve service quality and clinical outcomes for thousands of individuals served a

• 
  Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference14 April 2026, 12:05 pm

  LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS International Conference in Orlando, Florida, May 17-20, 2026. Oral Presentation Title: Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Mini Sympo

• Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing14 April 2026, 1:57 am

  SAN FRANCISCO--(BUSINESS WIRE)-- #AHFcares--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

• 
  NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 202613 April 2026, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.

• 
  Prodalim Expands Solos Technology Platform in the United States with New California Operations13 April 2026, 10:24 am

  WINTER GARDEN, Fla.--(BUSINESS WIRE)--Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its Solos platform in the United States with the launch of operations at a new facility in Hopland, California. The new site marks a key milestone in the continued globalization of Solos, Prodalim’s patented aroma recovery and beverage innovation platform, and positions Solos at the center of one of the world’s most important wine-producing regions, stre

• 
  Ayco Farms Clarifies FDA Enforcement Report Listing: No Active Recall and No Product in Market10 April 2026, 10:33 pm

  POMPANO BEACH, Fla.--(BUSINESS WIRE)--Ayco Farms, Inc. (“Ayco Farms”) today issued a clarification regarding recent media coverage tied to its inclusion in the U.S. Food and Drug Administration’s weekly Enforcement Report. The listing reflects a previously completed, voluntary recall of fresh whole cantaloupes that were distributed between December 12, 2025, and January 16, 2026, due to “potential” Salmonella contamination. There is no active recall, and no product subject to this notice is cur

• 
  AHF Slams Gilead for Role in Florida AIDS Drug Crisis10 April 2026, 5:01 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis

• 
  Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision10 April 2026, 12:00 pm

  JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision

• 
  Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients9 April 2026, 2:17 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced the publication of a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology demonstrating that its neuro-symbolic, multi-agent artificial intelligence platform can match cancer patients to clinical trials four times faster than conventional methods, with measurable accuracy, transparency, and equity, in routine clinical practice. The study, "Transforming oncology clinical t

• 
  Cartherics and Catalent Expand Commercial License Agreement9 April 2026, 12:00 pm

  MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p

• 
  American Ocean Minerals Corporation to Merge with Odyssey Marine Exploration, Inc., Creating a $1B U.S.-Controlled Deep-Sea Critical Minerals Platform8 April 2026, 11:30 am

  TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation (“AOMC”) and Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) (“Odyssey”) today announced they have entered into a definitive merger agreement to combine their businesses and create a leading deep-sea critical minerals research and resource extraction platform (the “Transaction”). The Transaction values the combined company at approximately $1 billion and includes a private placement of over $150 million from prominent institution

• 
  CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets7 April 2026, 5:13 pm

  MIAMI--(BUSINESS WIRE)-- #catsofinstagram--Petwealth raises $1.7M, advancing at-home pet PCR diagnostics, AI health insights, and key partnerships in vet telehealth and pet service software.

• 
  Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare7 April 2026, 1:00 pm

  MIAMI--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, and medical aesthetics practices that integrate ALASTIN’s comprehensive regenerative skincare portfolio into treatment planning and patient care. Colorado Springs Dermatology Clinic is the first ALASTIN Signature Practice, with additional Signature Practices planned across the United States in 2026

• PaceMate Appoints Cardiac Electrophysiologist and NIH-Funded Researcher Benjamin A. Steinberg, MD, MHS, FACP, FACC, FHRS as Chief Medical Officer7 April 2026, 12:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--PaceMate, a tech-enabled cardiac device monitoring platform managing care for more than 2.3 million patients at health systems nationwide, announced the appointment of Dr. Benjamin A. Steinberg as Chief Medical Officer. A nationally recognized leader in cardiac electrophysiology, NIH-funded researcher, and author of nearly 200 peer-reviewed publications, Dr. Steinberg brings to PaceMate a rare combination of clinical depth, research rigor, and real-world expertise

• 
  NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 20267 April 2026, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls

• 
  FDA Grants De Novo Classification to neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes7 April 2026, 11:00 am

  GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusion MRI data t

• 
  Allevion Medical™ Receives 510K Clearance for Vantage™ — A Fully Disposable Kit Featuring a Novel Approach to Spinal Decompression3 April 2026, 3:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)-- #AllevionMedical--Allevion Medical today announced the FDA clearance of Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally invasive lumbar decompression procedures. Developed to address pain associated with hypertrophic bone growth, Vantage™ enables targeted decompression through a patented approach that combines precision with procedural control. The system follows an intuitive, reproducible workflow—locate, dilate, decompress—that helps ph

• 
  CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 20262 April 2026, 8:05 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro

• 
  Partnership between Tasso and the Parkinson’s Foundation Reveals New Genetic Data31 March 2026, 12:00 pm

  NEW YORK & MIAMI & SEATTLE--(BUSINESS WIRE)-- #ParkinsonsAwarenessMonth--PD GENEration collaboration broadens participation in Parkinson’s genetic research through flexible, patient-centered blood collection.

• 
  TherapeuticsMD Announces Full Year 2025 Financial Results30 March 2026, 8:05 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

• 
  Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company30 March 2026, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #ashatherapeutics--Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company using AI-enabled molecular design technology

• 
  Kain Capital Completes Investment in White Wilson Medical Center and Appoints Brad Logan as CEO30 March 2026, 12:00 pm

  NEW YORK & FORT WALTON BEACH, Fla.--(BUSINESS WIRE)--Kain Capital LLC ("Kain") today announced the completion of its investment in White Wilson Medical Center, P.A. ("White Wilson"), the Emerald Coast’s largest independent multi-specialty physician group. Concurrent with the investment, Brad Logan has been appointed Chief Executive Officer. Founded in 1946, White Wilson has grown into the region’s leading independent physician group, operating nine clinic locations across Fort Walton Beach, Cre

• United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-230 March 2026, 11:00 am

  SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the change in absolute forced vital capacity (FVC) by 130.1 mL (Hodges-Lehmann [H-L] estimate, 95% confidence interval [CI], 82.2 to 178.1 m

• 
  Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 202627 March 2026, 12:15 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and

• Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract27 March 2026, 12:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus pr

• 
  StarLIMS to Acquire the MODA® Platform from Lonza, Expanding Deeper Into Manufacturing Operations & Quality Control25 March 2026, 1:00 pm

  HOLLYWOOD, Fla.--(BUSINESS WIRE)--StarLIMS has agreed to acquire the MODA® Platform, a trusted solution for manufacturing quality assurance and control in regulated environments. The transaction is expected to close in Q2 2026, subject to customary closing conditions. StarLIMS is a leading provider of enterprise laboratory informatics software. The acquisition of the MODA® Platform from Lonza, one of the world’s largest contract development and manufacturing organizations, will enable StarLIMS

• 
  Governor Signs Emergency Legislation Restoring HIV Medication Access for More Than 12,000 Floridians24 March 2026, 7:46 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Governor Ron DeSantis has signed into law emergency legislation restoring access to life-saving HIV medications for more than 12,000 Floridians who lost coverage when the Florida Department of Health cut the state’s AIDS Drug Assistance Program on March 1. The legislation, which passed both chambers of the Florida Legislature unanimously, appropriates $30.9 million in emergency bridge funding through June 30, 2026, restores Florida’s AIDS Drug Assistance

• 
  X-lumin Achieves Roundtrip Optical Transmission to LEO Satellite Using 15cm Portable Terminal24 March 2026, 6:07 pm

  MERRITT ISLAND, Fla.--(BUSINESS WIRE)-- #FreeSpaceOptics--X-lumin has successfully demonstrated a roundtrip optical transmission from its 15cm Optical Ground Terminal (OGT) to a retroreflector-equipped LEO satellite, and back, with the ability to track downlink signals that are 106 times dimmer than the current standard of 25µW/m2. The demonstration was repeated over multiple passes during recent testing, marking the first time a portable, low SWaP (Size, Weight, Power) terminal has closed a roundtrip optical lin

• 
  Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue20 March 2026, 8:17 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #Alzheimers--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential

• 
  Dentalcorp Launches First Annual Dental Technology Demo Day Offering US$100,000 Investment and Potential Pilot Opportunity19 March 2026, 12:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #DSO--Dentalcorp, one of North America's largest dental support organizations, today announced its inaugural Demo Day, a live dental technology competition taking place June 24 at the Gaylord Palms Resort & Convention Center in Orlando, Florida. The event will award a US$100,000 SAFE investment and a potential pilot opportunity to the winning company, with access to a network of more than 600 practices serving 5.7 million patients annually. Applications are open no

• 
  LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites19 March 2026, 11:30 am

  BOCA RATON, Fla.--(BUSINESS WIRE)-- #505b2--LGM Pharma’s additional investments in its Texas and Colorado sites will support growing demand for U.S.-based end-to-end pharma manufacturing.

• 
  Real Time Medical Systems to Present Data-Driven Strategies for Reducing Readmissions at AAPACN 202617 March 2026, 12:00 pm

  BALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its participation in the American Association for Post-Acute Care Nursing (AAPACN) 2026 Conference, taking place March 17–20 in Orlando, FL. As nursing professionals convene to explore best practices and emerging clinical innovations, Real Time and North Shore Health will highlight how live, data-driven approaches help post-acu

• 
  Redwire Elects The Honorable Frank Calvelli to Board of Directors17 March 2026, 11:30 am

  JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, today announced that its Board of Directors has elected The Honorable Frank Calvelli as its newest member, effective March 12, 2026. Calvelli previously served as Assistant Secretary of the Air Force for Space Acquisition and Integration and was the Pentagon’s first service acquisition executive for U.S. Space Force space systems and programs. In this role, Calvel

• 
  Renowned Radiosurgery Provider Fully Transitions to ZAP-X® Gyroscopic Radiosurgery® Platform, Marking New Era of Advanced Cranial Radiosurgery17 March 2026, 11:15 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that the Miami Neuroscience Center at Larkin Community Hospital has fully transitioned its stereotactic radiosurgery (SRS) program from earlier-generation cobalt-60 (Co-60)–based technology to the modern ZAP-X® Gyroscopic Radiosurgery® platform. Since December 2025, all cranial radiosurgery procedures at the center are now performed using the next-generation ZA

• 
  OpenEvidence and AAO-HNSF Pioneer a New Model for Updating Clinical Practice Guidelines16 March 2026, 1:00 pm

  ALEXANDRIA, Va. & MIAMI--(BUSINESS WIRE)--AAO-HNSF and OpenEvidence use AI to update clinical practice guidelines and align standards of care with the latest clinical evidence as it evolves.

• 
  NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling16 March 2026, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program.

• 
  Cryo-Cell Receives NYSE American Continued Listing Notice12 March 2026, 9:00 pm

  OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com

• 
  National Organization for Rare Disorders and OpenEvidence Partner to Bring AI-Powered Rare Disease Resources to Clinicians and Patients Worldwide12 March 2026, 1:00 pm

  NORWELL, Mass. & MIAMI--(BUSINESS WIRE)--NORD and OpenEvidence launch AI-powered, expert-reviewed rare disease resources for clinicians and patients to accelerate diagnosis and informed care.

• 
  Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients12 March 2026, 12:00 pm

  JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

• 
  Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo12 March 2026, 11:00 am

  MIAMI--(BUSINESS WIRE)-- #AIPoweredVisionDiagnostics--Heru, the leader in AI-powered vision diagnostics, announced it is showcasing the new PretestPro on its Heru wearable platform at Vision Expo 2026.

• 
  Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology12 March 2026, 11:00 am

  HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of T1N0M0 papillary thyroid microcarcinoma (PTM), a small, slow-growing, and most common form of thyroid cancer. The i

• 
  Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease11 March 2026, 2:45 pm

  WALTHAM, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscle, metabolic and rare diseases, today announced the presentation of new preclinical data on the lead therapeutic in its bioenergetics restoration franchise, PX578, at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. PX578, a first-in-class small molecule activator of the mitochondrial DNA polymer

• 
  Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases11 March 2026, 12:00 pm

  TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

• 
  NASA Awards Redwire $4 Million In Additional Funding to Support Trailblazing Drug Development in Microgravity11 March 2026, 11:00 am

  JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwire’s Pharmaceutical In-space Laboratory (PIL-BOX) technology. This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract

• 
  Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic Dose in the First Phase of Its Clinical Trial11 March 2026, 9:30 am

  EVRY, France--(BUSINESS WIRE)--The selected dose in the pivotal phase is lower than for other drug candidates in clinical trials or gene therapy drugs for Duchenne.

• 
  Starfighters Partners with Mu-GTech for Microgravity Flights10 March 2026, 12:00 pm

  CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world’s largest fleet of commercial supersonic aircraft, today announced a strategic partnership with Mu-G Technologies, LLC (“Mu-GTech”) to pursue microgravity flight missions for NASA, academic institutions and commercial research customers across the United States and Canada. The collaboration combines Starfighter

• 
  Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 202610 March 2026, 11:01 am

  DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 curre

• 
  NationsBenefits and Food City Partner to Expand Flex Card Access for Rx and OTC Health Needs Across Southeastern Communities10 March 2026, 11:00 am

  PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare benefits and fintech platform, today announced a new retail network integration with Food City, a trusted supermarket chain serving communities across Tennessee, Kentucky, Virginia, Georgia, and Alabama. Through this integration, eligible health plan members can use their NationsBenefits Mastercard® Prepaid Flex Card at all participating Food City locations to purchase approved food as medicine items, OTC health and wel

• 
  JECT Opens Its Ninth Location in West Palm Beach9 March 2026, 1:02 pm

  WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Leading medical aesthetics brand, JECT, has opened its newest location in West Palm Beach, FL.

• 
  NeuroPace to Present at the Leerink Global Healthcare Conference5 March 2026, 9:30 pm

  MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days

• 
  SonoThera Presents New Preclinical Data at MDA 2026 Highlighting RIPPLE™ as an Efficient, Scalable, Nonviral Platform for Full-Length Dystrophin Delivery in DMD5 March 2026, 5:30 pm

  SAN FRANCISCO--(BUSINESS WIRE)-- #DMD--SonoThera™, a biotechnology company dedicated to addressing the root causes of disease through next-generation genetic medicines, today announced it will present at the annual Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11th in Orlando, Florida. The oral presentation will highlight SonoThera’s proprietary RIPPLE™ (Remote Induction of Pulsed Pressure Lateral to Energy) technology and its ability to enable delivery

• 
  Dr. Jeffrey Kotzen Transitions Concierge OB/GYN Practice to Membership-Based Women’s Healthcare in Palm Beach Gardens5 March 2026, 4:30 pm

  PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Dr. Jeffrey Kotzen, a Yale-trained obstetrician-gynecologist (OB/GYN) with more than four decades of experience, has announced the expansion of his long-standing concierge practice into a membership-based women’s healthcare model in Palm Beach Gardens. Built in partnership with Monarch, a company that helps physicians offer high-quality, membership-based care models for women’s health, the practice preserves the time and access patients value while exp

• 
  Arcturus Therapeutics to Attend Upcoming Investor Conference5 March 2026, 2:00 pm

  SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events secti

• 
  Savara Announces Participation in 2026 Citizens Life Sciences Conference4 March 2026, 9:05 pm

  LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on Wednesday, March 11th at 10:10am ET in Miami, FL. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archiv

• 
  Harmony Biosciences to Participate in Upcoming Investor Conferences4 March 2026, 1:05 pm

  PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical co

• 
  Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference3 March 2026, 9:05 pm

  SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors sectio

• 
  Align Technology to Speak at Upcoming Financial Conferences3 March 2026, 9:01 pm

  TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. As noted below, the presentations will be webcast live via the Investor Relations section of Align Te

• 
  Landmark digiiMED Study in Puerto Rico Utilizing Smart Meter Cellular-Connected Devices Helps 54% of Uncontrolled Hypertension Patients Achieve Blood Pressure Control3 March 2026, 2:00 pm

  TAMPA, Fla. & SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Smart Meter, the number one supplier of technology and services for remote patient monitoring, and digiiMED, a leader in technology-enabled clinical services for value-based care, today announced the results of a high-impact hypertension management pilot conducted across three Federally Qualified Health Centers (FQHCs) in Puerto Rico. digiiMED also announced plans to expand their offering into the continental United States, bringing their RP

• 
  Veradermics to Participate in Upcoming March Investor Conferences3 March 2026, 12:00 pm

  NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a firesid

• 
  PepGen to Participate in the Leerink Global Healthcare Conference3 March 2026, 12:00 pm

  BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available

• 
  Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference3 March 2026, 12:00 pm

  WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “

• United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference3 March 2026, 12:00 pm

  SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, from 1:00 to 1:30 p.m. EDT, at the Leerink Global Healthcare Conference in Miami Beach. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An

• 
  Spruce Biosciences to Present at Upcoming Investor Conferences in March2 March 2026, 9:05 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global Healthcare Conference Date and Time: March 9, 2026, at 11:20 a.m. ET Format: Firesid

• Queen Latifah Headlining Spring Break Concert to Raise Funds for HIV/AIDS Awareness2 March 2026, 2:45 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Grammy, Emmy, Golden Globe, NAACP, SAG and Critic’s Choice award-winning and Oscar-nominated musician, actress, producer, label president, author and entrepreneur will headline AIDS Healthcare Foundation’s 21st Annual Florida AIDS Walk & Music Festival presented by AHF Pharmacy, Fed Ex and Wells Fargo at Fort Lauderdale Beach on Saturday, March 21, 2026. The annual 5k walk and concert, which recently celebrated its 20th anniversary, has raised millions

• 
  PVP Labs to Showcase Breakthrough Peptide Therapy Pipeline and Non-Addictive Analgesic, Taphalgin®, at LSX Investival Showcase USA in Miami2 March 2026, 1:28 pm

  MIAMI--(BUSINESS WIRE)-- #AddictionPrevention--PVP Labs to present Taphalgin®, a first-in-class non-addictive analgesic, and advanced peptide drug platform at LSX Investival Showcase USA in Miami.

• 
  Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 202527 February 2026, 10:00 pm

  OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue

• 
  Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27 February 2026, 6:00 am

  ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami a

• 
  Summit Therapeutics to Present at Upcoming Investor Conferences26 February 2026, 11:45 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday

• 
  Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA26 February 2026, 10:00 pm

  MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the futur

• 
  Vir Biotechnology to Participate in Upcoming Investor Conferences26 February 2026, 9:05 pm

  SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts. Leerink Partners Global Healthcare Conference: Marianne De Backer, M

• AHF Sues Florida to Block Fake Emergency Rule that Cuts AIDS Drugs to 16,00026 February 2026, 5:50 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--This morning AIDS Healthcare Foundation (AHF) filed an administrative action to challenge the validity of the emergency rule enacted by the Florida Department of Health, prior to a hearing scheduled yesterday morning with State Administrative Law Judge W. David Watkins. The Florida Department of Health has invoked emergency powers designed to protect public health in order to cut 16,000 Floridians off their HIV medications. On the eve of a court hearing chall

• 
  AGBT Names 2026 Next Gen Leadership Award Recipients for General Meeting26 February 2026, 4:20 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #AGBT--AGBT today announced the recipients of the 2026 Next Gen Leadership Awards for the AGBT General Meeting. These awards recognize outstanding early-career researchers and graduate students whose work and potential are advancing innovation across genomics and related disciplines. Through the Next Gen Leadership Awards, recipients receive financial support to attend and present their research at the AGBT General Meeting, fostering scientific exchange, professional gr

• 
  Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences26 February 2026, 2:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

• 
  Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress26 February 2026, 1:30 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida. At MDA 2026, Sarepta will present new and ongoing evidence across its rare neuromuscular portfolio, including commercially available gene therapy and exon-skipping treatments in Duchenne muscular dystrophy. Presen

• 
  Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 202626 February 2026, 1:00 pm

  SAN JOSE, Calif.--(BUSINESS WIRE)-- #NGS--Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

• 
  Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base26 February 2026, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and connectivity solution intended to expand advanced operating capabilities across the Company’s SRT-100™ system installed base. Through the combination of a new point-of-care software solution with cl

• 
  Tartar Shield Launches “Second Smile” Initiative Integrating Preventive Dental Care Into Shelter Adoptions for 120+ Dogs in Recognition of National Pet Dental Health Awareness Month25 February 2026, 4:00 pm

  NOBLESVILLE, Ind.--(BUSINESS WIRE)-- #AdoptDontShop--Tartar Shield® partners with Second Shot Adoption Photos to boost shelter dog adoption and advance preventive canine oral health.

• 
  Catalyst OrthoScience Announces FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty25 February 2026, 3:00 pm

  NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Archer® Patient-Specific Instrumentation (PSI). Licensed in partnership with 3D-Side, Archer PSI is a full suite of humeral and glenoid guides tailored to the patient’s anatomy that allow orthopedic surgeons to execute their 3D p

• 
  GeneDx to Participate in Upcoming Investor Conferences25 February 2026, 1:30 pm

  GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.

• 
  Dexcom Announces Upcoming Conference Presentation25 February 2026, 1:30 pm

  SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D

• 
  Ardent Health and hellocare.ai Partner to Implement Enterprise AI Assisted Virtual Physician, Nursing, Patient Safety and Intelligent Care Delivery25 February 2026, 1:00 pm

  BRENTWOOD, Tenn. & CLEARWATER, Fla.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced it has partnered with hellocare.ai as its enterprise platform for AI assisted virtual physician, virtual nursing, virtual patient observation and advanced patient safety capabilities. The deployment will span more than 2,000 patient rooms and support a broad range of inpatient care environments. Through this pa

• 
  Evolus to Participate in The Leerink Partners Global Healthcare Conference25 February 2026, 1:00 pm

  NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the

• 
  NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types25 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

• 
  Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR25 February 2026, 12:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical

• 
  Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March24 February 2026, 9:05 pm

  ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, March 10 in Miami. 2026 Citizens Life Scie

• 
  DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences24 February 2026, 2:23 pm

  MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts  Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, Mar

• 
  Schrödinger to Participate in Upcoming Investor Conferences24 February 2026, 1:30 pm

  NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat on Tuesday, March 3, 2026 at 9:50 a.m. E.T. Leerink Global Healthcare Conference 2026: Fireside chat on Tuesday, March 10, 2026 at 1:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 17, 2026 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section

• 
  Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference24 February 2026, 1:00 pm

  WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com, with a replay accessible shortly after the presentation concludes. About Th

• 
  OmniAb to Participate at the Leerink Partners Global Healthcare Conference24 February 2026, 1:00 pm

  EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners repr

• 
  Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications24 February 2026, 12:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet

• 
  Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference24 February 2026, 12:00 pm

  TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida. Oral presentations feature data from the completed Phase

• 
  908 Devices to Participate in Investor Conferences in March24 February 2026, 12:00 pm

  BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences. TD Cowen 46th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 4 at 9:10 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Monday, March 9 at 1:40 p.m

• 
  Gilead Sciences to Present at Upcoming Investor Conferences23 February 2026, 9:05 pm

  FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time The live webcasts can be accessed at the company’s investors pa

• 
  Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 202523 February 2026, 9:05 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and year ended December 31, 2025. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi

• 
  Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences23 February 2026, 9:05 pm

  SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company’s website, acadia.com, under the investors section

• AHF Secures Emergency Hearing to Challenge Florida's Planned Cuts to HIV Drug Program23 February 2026, 8:40 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--An Administrative Law Judge today ordered an emergency hearing for Wednesday, February 25, in AIDS Healthcare Foundation's legal challenge to the Florida Department of Health's plan to slash eligibility for the state's AIDS Drug Assistance Program, known as ADAP. Beginning March 1, the Department plans to cut the qualifying income for the program from roughly $62,600 to $21,000 for an individual, dropping thousands of Floridians living with HIV from the cover

• 
  OSSIOfiber® Minimally Invasive All-Natural Bunion Correction System Improves, Simplifies Surgical Procedure for Patients and Physicians23 February 2026, 3:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--With the launch today of OSSIOfiber® Minimally Invasive All-natural (MIA) Bunion Correction System, OSSIO Inc. — a fast-growing medical technology company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants — takes a major step forward in perfecting bunionectomy for surgeons and patients and significantly expands its footprint in a fast-growing multimillion-dollar industry. As with all OSSIOfiber implants, the 4.5x70mm beveled

• 
  Alto Neuroscience Announces Participation in Upcoming Investor Conferences23 February 2026, 1:33 pm

  MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50

• 
  biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research23 February 2026, 1:30 pm

  CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s duet multiomic solutions are compatible with Element Biosciences AVITI24™ 5D multiomics and AVITI™ sequencing instruments. Validated at the University of Minnesota (UMN) Genomics Center, this integration delivers enhanced sensitivity for applications including cancer, aging, and neurodegenerative disease with t

• 
  Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum23 February 2026, 12:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,

• 
  Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology23 February 2026, 11:00 am

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology

• 
  enGene to Participate in Upcoming Investor Conferences20 February 2026, 1:00 pm

  BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Ann

• 
  Veracyte to Participate in Upcoming Investor Conferences19 February 2026, 10:00 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference – Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the company’s presentations will be available by vi

• 
  Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights19 February 2026, 9:05 pm

  DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

• 
  Unified Women’s Healthcare Responds to Rising Demand for Menopause Care19 February 2026, 2:05 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Unified Women’s Healthcare (Unified), in partnership with its OBGYN affiliates, is expanding access to perimenopause and menopause care nationwide through Unified for You, its patient resource platform and corresponding awareness campaign, which initially launched in Florida earlier this month. Recent data shows many women experience years of untreated menopause-related conditions before receiving appropriate care, highlighting the importance of timely counseling,

• Vizgen to Debut Spatial Multi-Omics Roadmap at AGBT 202619 February 2026, 2:00 pm

  WALTHAM, Mass.--(BUSINESS WIRE)-- #Vizgen--Vizgen, Inc., a leader in spatial multi-omics at single-cell resolution, today announced a series of innovations under development to help accelerate drug discovery, advance understanding of disease progression, and enable new research breakthroughs. The company will present its roadmap at the Advances in Genome Biology and Technology (AGBT) General Meeting, February 23-26, in Orlando, FL. Among planned topics, Vizgen will cover advances through its collaboratio

• 
  Doc.com Expands U.S. Rollout with Florida Launch, Advancing AI-Powered Blockchain Secured Healthcare Access19 February 2026, 2:00 pm

  NEW YORK--(BUSINESS WIRE)--Doc.com, the pioneering healthcare technology company redefining access to care through artificial intelligence and blockchain integration, today announced the launch of its telemedicine platform in Florida as part of its ongoing United States expansion. The Florida rollout marks a significant milestone in the company’s multi-phase national growth strategy. Through a seamless mobile experience, Florida residents can now connect with licensed healthcare professionals w

• 
  Atrandi Biosciences Redefines Single-Cell Multiomics with Expanded SPC Innovator Kit Portfolio19 February 2026, 1:03 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #AGBT26--Atrandi Biosciences announced the launch of its new 170 µm and 300 µm SPC Innovator Kits.

• 
  Aptar to Participate in Upcoming Investor Conferences18 February 2026, 10:00 pm

  CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences

• 
  Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology18 February 2026, 1:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus’ superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structure

• 
  CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference18 February 2026, 1:00 pm

  BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026. About CareDx CareDx is a precision medicine company de

• 
  Catalent and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A918 February 2026, 1:00 pm

  TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease. TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The program reflects years

• 
  Scholar Rock to Present at Upcoming Investor Conferences18 February 2026, 1:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Schol

• 
  NeoGenomics to Participate in Upcoming Investor Conferences18 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.

• 
  Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference18 February 2026, 12:01 pm

  DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking plac

• 
  Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March18 February 2026, 12:00 pm

  BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in upcoming investor conferences in February and March.

• 
  Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 202617 February 2026, 10:05 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our

• Advocates Rally at Florida Capitol to Protect Lifesaving HIV Drug Access for Thousands, says AHF17 February 2026, 9:47 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--Advocates Rally at Florida Capitol to Protect Lifesaving HIV Drug Access for Thousands

• 
  Mirada and Angeline Among America's Top Master-Planned Communities of 202517 February 2026, 2:00 pm

  TAMPA BAY, Fla.--(BUSINESS WIRE)--Metro Development Group’s Mirada and Angeline have been named among the nation’s top-selling master-planned communities in 2025, earning recognition from John Burns Research & Consulting and RCLCO, two of the real estate industry’s leading research organizations. Together, the two Pasco County communities ranked in the Top 40 nationally, driven by more than strong sales alone. From Mirada’s 15-acre world-class lagoon–the largest in the U.S.--and vibrant eve

• 
  NeoGenomics Reports Fourth Quarter and Full Year 2025 Results17 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.

• 
  NationsBenefits and Kinney Drugs Partner to Expand Flex Card Access for Rx and OTC Health Needs in New York17 February 2026, 12:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits, the leading healthcare fintech and supplemental benefits platform, announced a new partnership with Kinney Drugs, a trusted, employee-owned pharmacy and retail chain serving communities across New York and Vermont. Through this integration, eligible health plan members will be able to use their NationsBenefits Benefits Mastercard® Prepaid Flex Card at participating Kinney Drugs locations to purchase eligible prescription (Rx) medications, OTC

• 
  BeOne Medicines to Present at Upcoming Investor Conferences17 February 2026, 11:00 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Glo

• Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference12 February 2026, 9:30 pm

  ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will present at the Raymond James Institutional Investors Conference in Orlando, Florida on Monday, March 2 at 1:40 p.m. Eastern Time. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay of the webcast will be accessible shortly after the event and will remain available for 90 days. About Guardian Pharmacy Services Guardian Pharmacy Servi

• Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer12 February 2026, 9:05 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025. Highlights include the following: Revenues were $4.9 million for the quarter and $27.5 million for the year Net loss was $3.2 million for the quarter and $7.7 milli

• 
  Sindre Zeiner-Gundersen Joins Joi Scientific12 February 2026, 7:00 pm

  MERRITT ISLAND, Fla.--(BUSINESS WIRE)--Joi Scientific is pleased to welcome Sindre Zeiner-Gundersen as the company’s Advanced Plasma & Resonant Energy Physicist. Sindre will lead Joi’s scientific activities including all aspects of Joi’s science program. Sindre is a quantum physics expert who previously served as CEO/President of Nornec AS, a Norwegian consulting and engineering services company. Nornec has been a consultant to Joi since 2024. At Nornec, Sindre provided consulting and R&amp

• 
  NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection12 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.

• 
  Avanti Capital Advances Impact-Driven Investing and Expands Commitment to Philanthropy12 February 2026, 5:00 am

  BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital funds longevity fellowship, expanding its commitment to geroscience research and impact-driven philanthropy.

• Florida Health Dept. Proposes New Formal Rule to Slash HIV Drug Access for Thousands, Notes AHF11 February 2026, 3:19 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Florida Health Dept. Proposes New Formal Rule to Slash HIV Drug Access for Thousands

• 
  HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Named a 2026 Edison Awards Finalist10 February 2026, 1:05 pm

  DURHAM, N.C.--(BUSINESS WIRE)-- #Childbirth--HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the Women’s Health and Reproductive Innovations category of the world-renowned 2026 Edison Awards. The Company’s point-of-care solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded use of its Quantra Hemostasis System with QStat® Ca

• 
  ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10 February 2026, 1:00 pm

  WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharm

• Super Buddha to Live Paint at 2026 Hispanic Prosperity Gala on Feb 10th at Mar-a-Lago9 February 2026, 10:38 pm

  PALM BEACH, Fla.--(BUSINESS WIRE)--Venezuelan-born contemporary artist Super Buddha announced today he will present a live painting experience on the red carpet at the Hispanic Prosperity Gala, presented by Latino Wall Street, taking place February 10, 2026, at the Mar-a-Lago Club. This landmark event reflects the growing support of the Latino community for conservative values and their historic turnout for President Donald Trump in the last election. The event will convene a distinguished rost

• Forte Biosciences, Inc. to Present at Upcoming Investor Meetings9 February 2026, 9:01 pm

  DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will

• 
  Trividia Health, Inc. Initiates Labeling Correction for all TRUE METRIX® Blood Glucose Monitoring Systems6 February 2026, 6:00 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner’s Booklets/System Instructions for Use for all TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO Blood Glucose Monitoring Systems (collectively, the “Products”) distributed in the United States, United Kingdom, Mexico, Australia, and the Caribbean. Trividia is updating the E-5 Error Code in the “Messages” section of

• Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 20265 February 2026, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and ans

• 
  X‑BATT Files Patent to Advance Safer Lithium-Ion Battery Storage and Operation4 February 2026, 5:59 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--X-BATT today announced it has filed a U.S. patent application covering new materials and designs aimed at improving the safety of lithium-ion batteries during assembly, transportation, operation, and storage. This innovation promotes safer and more resilient batteries in real-world conditions, ultimately focusing on lowering fire risk during deep discharge and extended storage, situations common in homes, vehicles, and warehouses. From smartphones to EVs, lithium

• 
  RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts4 February 2026, 1:00 pm

  SAN MATEO, Calif.--(BUSINESS WIRE)-- #DeepClinicalAI--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced details of 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, held February 4-6, at the Ernest N. Morial Convention Center in New Orleans. The abstracts span aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization. Findings reflect the impact of deep clinical AI delivered

• 
  Guardant Health to Participate in Upcoming Investor Conferences3 February 2026, 9:05 pm

  PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 10th TD Cowen 46th Annual Health Care Conference in Boston, MA Fireside chat on Wednesday, March 4th at 9:50 a.m. Eastern Time Leerink Partners Global He

• 
  Orthopedic Medical Technology Company Celebrates Grand Opening of U.S. Headquarters With Business, Government and Healthcare Leaders3 February 2026, 7:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--OSSIO Inc., a fast-growing medical technology company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants, celebrated the grand opening of its new U.S. headquarters in Manatee County’s City of Palmetto yesterday with Florida’s lieutenant governor and more than 50 other business, government and healthcare leaders. OSSIO selected Florida to expand its operations, which started in Israel in 2014, because of the state’s compelling

• Florida Health Department Retreats on HIV/AIDS Drug Cuts3 February 2026, 5:57 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In a notice published earlier today, the Florida Department of Health (DOH) retreated on its decision to make cuts to the State's AIDS drug program, which provides life-saving medications and health insurance support to over 30,000 Floridians living with HIV/AIDS. Alleging that an undocumented $120 million budget shortfall necessitated the cuts, the cuts to the program, originally scheduled to be enacted on March 1st, would adversely impact the life-savin

• 
  Publix Pharmacy Provides Savings on Certain GLP-1 Medications3 February 2026, 3:30 pm

  LAKELAND, Fla.--(BUSINESS WIRE)--Publix Pharmacy is currently offering savings on select GLP‑1 therapies through a discount card program. For a limited time, eligible Publix Pharmacy customers can have their prescriptions for the newly introduced Wegovy (semaglutide) 1.5 mg or 4 mg tablet filled at pricing starting as low as $149 per month, and Wegovy and Ozempic (semaglutide) 0.25 mg and 0.5 mg injectables starting as low as $199 per month. Obtaining the reduced price Customers can speak with

• 
  RxUtility and Buzz Health Partner to Boost Medication Price Transparency for Consumers3 February 2026, 2:15 pm

  NASHVILLE, Tenn. & FORT WALTON BEACH, Fla.--(BUSINESS WIRE)-- #AffordabilityCrisis--RxUtility, a medication affordability toolkit, announced a partnership with Buzz Health, leveraging its RxCompare multi-discount card pricing API.

• 
  Family Heart Foundation Teams Up with Former NFL Quarterback Matt Hasselbeck to Launch “Tackle Cholesterol™: Get into the LDL Safe Zone®”3 February 2026, 1:03 pm

  FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #HeartMonth--Former NFL quarterback, Matt Hasselbeck, and the Family Heart Foundation team up to raise awareness of high cholesterol as a risk for heart disease.

• 
  Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End "Referral Black Holes" in Oncology2 February 2026, 2:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Massive Bio today announced the launch of TrialRelay™, a physician-facing enrollment orchestration platform designed to eliminate one of oncology’s most persistent failures: patients getting lost after a clinical trial referral. The announcement will be made during the SCOPE Conference 2026, the leading global forum for clinical operations and innovation. For years, Massive Bio’s physician platform operated under the name Clinical Network. While accurate, the ter

• 
  Boyd to Exhibit at Medical Design & Manufacturing (MD&M) West 2026 in Anaheim, California2 February 2026, 1:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)-- #Boyd--Boyd, a leader in advanced materials and medical wearable solutions, will exhibit at MD&M West, taking place February 3 -5, 2026 in Anaheim, California. Boyd experts will be on site to highlight the latest advancements in stick-to-skin biosensors, medical wearables, display technologies, and medical-grade disposables. With deep expertise in materials science and precision engineering, Boyd partners with leading healthcare innovators to develop patient focu

• AHF Receives Expedited Florida Hearing Opposing ADAP Reductions31 January 2026, 12:32 am

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Receives Expedited FL Hearing Opposing ADAP Reductions

• 
  Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)30 January 2026, 9:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock. Awards were made to 20 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee

• Not On Our Watch! AHF Continues to Stand Up Against Florida Eliminating HIV/AIDS Care30 January 2026, 3:06 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In continuing to stand up against the proposed cuts to Florida’s AIDS Drug Assistance Program (ADAP), advocates with AIDS Healthcare Foundation (AHF) will host simultaneous protests at the local department of health offices in Orlando, Florida and St. Petersburg, Florida. Taking place at 10:30am ET on Friday, January 30, 2026, the protests will take place at 205 Dr. Martin Luther King, Jr. Street North, St. Petersburg, FL and 932 W. Central Blvd., Orlando

• 
  Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy29 January 2026, 12:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA

• 
  CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results28 January 2026, 9:05 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to dilute

• 
  New UCF Research Indicates C-BATT’s Obsidia™ Swells Less Than Graphite During Lithiation28 January 2026, 4:13 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--As global demand increases for affordable, longer-lasting, high-capacity energy storage, new research suggests C-BATT’s Obsidia™ could help solve one of the most persistent causes of failure in lithium-ion batteries: material swelling during cycling. University of Central Florida (UCF) professor Dr. Akihiro Kushima, a leader in the field of in situ transmission electron microscopy, presented the findings at the 50th Annual International Convention and Expo on Adv

• 
  I/ONX and Mote Marine to Collaborate on Incorporating AI Compute into Marine Science Research28 January 2026, 2:00 pm

  LAS VEGAS & SARASOTA, Fla.--(BUSINESS WIRE)--I/ONX High Performance Compute and Mote Marine Laboratory, Inc. are partnering to incorporate AI and heterogeneous compute into marine research.

• 
  Medable Introduces AI Agent to Reduce Burden at Research Sites By Assisting Principal Investigators with Oversight of eCOA Data28 January 2026, 12:00 pm

  PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of fun

• 
  Premier Radiology Services Acquires NRAD, Further Expanding Teleradiology Capabilities28 January 2026, 11:30 am

  DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Premier Radiology Services Acquires NRAD, Further Expanding Teleradiology Capabilities

• UF Health Transplant Specialties Again Rank Among Nation’s Best27 January 2026, 3:28 pm

  GAINESVILLE, Fla.--(BUSINESS WIRE)--UF Health transplant programs continue to be among the nation’s elite, including best-in-category results for the UF Health lung transplant program, according to reports released earlier this month by the Scientific Registry of Transplant Recipients, or SRTR. “Treatment at UF Health centers on individualized care, quality of life and long-term outcomes,” said Thiago Beduschi, M.D., director of the Abdominal Transplant Center. “That means providing patients wi

• 
  AdhereTech Appoints Jeremy Gilbert as CEO to Accelerate Growth Across Clinical Trials and Commercial Adherence Programs27 January 2026, 1:00 pm

  SUMMIT, N.J.--(BUSINESS WIRE)--AdhereTech, a leader in real-time medication adherence smart devices, today announced the appointment of Jeremy Gilbert as chief executive officer. Gilbert, who previously served as AdhereTech’s chief product development officer, brings more than 20 years of experience building and scaling digital health, life sciences, and enterprise technology solutions that improve patient outcomes and protect critical research and commercial investments. The appointment reflec

• 
  NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 202627 January 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.

• 
  Legislation In Florida Seeks To Increase Access To Genetic Testing22 January 2026, 10:05 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) for introducing legislation that would eliminate financial barriers for patients requiring clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing. Germline testing is a type of test that looks for inherited mutations that have been present

• 
  Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES22 January 2026, 12:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #ConceptMedical--Concept Medical Inc. is proud to announce the successful enrollment of the first patients in the STARS DAPT randomized controlled trial.

• 
  Starfighters Completes Wind Tunnel Testing for STARLAUNCH 121 January 2026, 1:00 pm

  CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, today announced the successful completion of wind tunnel testing for STARLAUNCH 1, a key technical milestone in the Company’s air-launched rocket development efforts. The completed test campaign evaluated separation of the STARLAUNCH 1 vehicle from the Starfigh

• 
  SurGenTec® Secures FDA Clearance for ION-C™ Facet Fixation System — Designed to Support Fusion While Preserving Alignment20 January 2026, 7:32 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec®, a medical device innovation company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-C™ Facet Fixation System. ION-C™, part of SurGenTec®’s posterior cervical platform, has received expanded indications allowing for the treatment of cervical pseudoarthrosis when implanted bilaterally within the facet joints. This clearance is supported by compelling long-term clinical evidence from an

• 
  Smart Meter Launches iGlucose® Touch, a Touchscreen, Cellular-Connected Blood Glucose Meter Built for Modern RPM20 January 2026, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--As demand accelerates for simpler, more reliable remote patient monitoring solutions, Smart Meter, the leading supplier of cellular-enabled Remote Patient Monitoring (RPM) devices, data, and services, today announced the launch of iGlucose® Touch, a next-generation blood glucose monitoring system engineered to modernize glucose testing while delivering dependable, real-time data to care teams. Purpose-built for RPM, iGlucose Touch addresses long-standing challenges

No Feed

No Feed

No Feed

No Feed

No Feed